A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

Investigational New Drugs

Volumn 24, Issue 5, 2006, Pages 435-439

  Knowling, M ^a   Blackstein, M ^b   Tozer, R ^c   Bramwell, V ^d   Dancey, J ^e   Dore, N ^f   Matthews, S ^f   Eisenhauer, E ^f  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d TOM BAKER CANCER CENTRE   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Queen's Cancer Research Institute   (Canada)

Author keywords

Acetylphospholipid; Advanced soft tissue sarcoma; Akt; MAP kinase; Perifosine; Phase II; Protein kinase C; SAPK JNK pathway

Indexed keywords

D 21226; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PHOSPHOLIPID DERIVATIVE; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; REGULATOR PROTEIN;

ADULT; ARTICLE; BLOOD TOXICITY; CANADA; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMICAL ANALYSIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; ENZYME INHIBITION; FATIGUE; HEALTH CARE ORGANIZATION; HUMAN; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT REFUSAL; TREATMENT RESPONSE;

ACADEMIES AND INSTITUTES; ADULT; AGED; ANTINEOPLASTIC AGENTS; CANADA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHORYLCHOLINE; SARCOMA;

EID: 33745055718     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-6406-7     Document Type: Article

References (21)

1. Bramwell VH, Anderson D, Charette ML, Sarcoma Disease Site G (2003) Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database of Systematic Reviews (3):CD003293
2. Verma S, Bramwell V (2002) Dose-intensive chemotherapy in advanced adult soft tissue sarcoma. Exp Rev Anticancer Ther 2(2):201-215
3. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480
4. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. International J Cancer 100(6):623-626
5. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225. J Clin Oncol 23(4):866-873
6. Verweij J, Van Oosterom A, Blay JY, Judson I, Rodenhuis S, Van Der Graaf W, Radford J, Le Cesne A, Hogendoorn PCW, Di Paola ED, Brown M, Nielsen OS (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Europ J Cancer 39(14):2006-2011
7. Uberall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke H (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51(3):807-812
8. Ruiter GA, Zerp SF, Bartelink H, Van Blitterswijk WJ, Verheij M (1999) Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59(10):2457-2463
9. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2(11):1093-103
10. Cuadrado A, Issing W, Fleming TP, Molloy CJ (1994) Uneven distribution of protein kinase C-alpha and -beta isozymes in human sarcomas and carcinomas. J Cell Physiol 159(3):434-440
11. Issing WJ, Wustrow TP (1991) Overexpression of protein kinase-C-isoenzymes in human tumor cell lines. Laryngo-Rhino-Otologie 70(3):146-150
12. Unger C: Study D-21266-3040 AOI Phase I study Group. Unpublished data
13. Unger C: Study D-21266-3087. Weekly enteric coated tablets. AOI Phase I study Group. Unpublished data
14. Crul M, Rosing H, De Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JHM, Beijnen JH, Ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Europ J Cancer 38(12):1615-1621
15. Monga M, Messmann R, Headlee D, Woo EW, Figg WD, Murgo A, Sausville EA: A Phase I trial of oral perifosine in patients with refractory neoplasms: ASCO, 2002, pp #1837
16. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G (2004) A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450-7456
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J National Cancer Inst 92(3):205-216
18. Zee B, Melnychuk D, Dancey J, Eisenhauer E (1999) Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Statist 9(2):351-363
19. Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E (2002) Multinomial Phase II Trial Designs. J Clin Oncol 20(2):599
20. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM (2002) Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62(5):1401-1409
21. Ruiter GA, Zerp SF, Bartelink H, Van Blitterswijk WJ, Verheij M (2003) Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti Cancer Drugs 14(2):167-173